←
George W Sledge MD777 posts
George W Sledge MD avatar

George W Sledge MD

@GeorgeSledge51

Ancillary Clinical Professor of Medicine, Stanford University; breast cancer doc and Chief Medical Officer, Caris Life Sciences

◷ Joined August 2013▧ 9 Photos and videos
Caris Life Sciences avatar
⟳ George W Sledge MD retweeted
Caris Life Sciences@carisls·Oct 27

Could multimodal AI help identify which patients with early-stage HR+ breast cancer may benefit from extended endocrine therapy? In an NSABP B-42 cohort, significant benefit was observed in about one-quarter of patients the models classified as both high risk for late distant recurrence and likely to benefit from extended therapy. #ESMOAI26. ow.ly/Rqh15101alG

Post attachmentPost attachment
The Cancer Letter avatar
⟳ George W Sledge MD retweeted
The Cancer Letter@TheCancerLetter·Jun 20

Ian Krop named section chief of Medical Oncology and Hematology and deputy director for Clinical Affairs for @YaleCancer cancerletter.com/in-brief/20…

Paolo Tarantino avatar
⟳ George W Sledge MD retweeted
Paolo Tarantino@PTarantinoMD·Jun 3

Every ASCO has some hidden pearls. One that I had the luck to attend was a presentation by Gil Shamai on the discordance between AI prediction and standard path features — wonderfully discussed by David Rimm. Highly recommended. “AI errors are not bugs, but rather features”

Post attachmentPost attachmentPost attachmentPost attachment
Oncology Times avatar
⟳ George W Sledge MD retweeted
Oncology Times@OncologyTimes·May 7

A care model led by Manali Patel, MD, MPH, a Stanford thoracic oncologist, demonstrated that trained lay health staff can improve patient experiences, reduce emergency department visits, and lower overall #healthcare costs. ow.ly/4xlG50YW66U

Post attachment
Raffaele Colombo avatar
⟳ George W Sledge MD retweeted
Raffaele Colombo@raffcolo·20 Dec 2025

Possible mechanisms of resistance to T-DXd in breast cancer patients using real-world data and multiomic profiling ⬆️ABCC1 and ⬇️ERBB2 showed ⬇️OS, in line with previous works on T-DXd. Presented at #SABCS24, now published on @Nature_NPJ by @GeorgeSledge51 et al. (link below)

Post attachmentPost attachmentPost attachmentPost attachment
Mirrors of Medicine avatar
⟳ George W Sledge MD retweeted
Mirrors of Medicine@mirrorsmed·1 Jul 2025

A Real-World Experience in Pan-Tumor Testing for HER2 IHC in More Than 65 000 Solid Tumors jamanetwork.com/journals/jam… Trastuzumab deruxtecan-nxki (T-DXd) received tumor-agnostic FDA approval in April 2024 for adults with unresectable or metastatic HER2-positive (IHC 3+) solid tumors lacking other treatment options, based on responses seen across three DESTINY trials. This prompted widespread HER2 IHC testing across tumor types, leading to the first large-scale report on real-world HER2 IHC 3+ prevalence using standardized interpretation criteria. Among over 65,000 tested patients, HER2 IHC 3+ rates varied widely by cancer type, with #BladderCancer showing the highest prevalence (13.9%), while others—like gliomas, sarcomas, #ProstateCancer, and kidney cancers—had minimal or no expression. These findings suggest universal HER2 testing may not be necessary for all solid tumors, and a more targeted approach—initiating HER2 IHC only after identifying ERBB2 amplification or overexpression via comprehensive genomic profiling—could reduce unnecessary testing while optimizing workflow and cost-efficiency. Dave Bryant Rebecca Feldman Farah Abdulla Daniel Magee Jennifer R. Ribeiro Matthew Oberley Milan Radovich David Spetzler @carisls @GeorgeSledge51

Post attachment
Caris Life Sciences avatar
⟳ George W Sledge MD retweeted
Caris Life Sciences@carisls·20 Mar 2025

Caris has published a 295,000+ patient study revealing variable efficacy among cancers for patients treated with tissue-agnostic drugs and uncovering the potential for expanding approvals to other drugs in the same class. Learn more: ow.ly/Ii5x50VlbqJ

Post attachment
Caris Life Sciences avatar
⟳ George W Sledge MD retweeted
Caris Life Sciences@carisls·29 Oct 2024

Caris Chief Scientific Officer Milan Radovich, PhD, shares insights on how Caris Assure sets a new benchmark in #liquidbiopsy profiling. Join us in transforming patient care through innovative solutions: ow.ly/4LGf50TVt28

2:09
George W Sledge MD avatar
George W Sledge MD@GeorgeSledge51·7 Dec 2023

Also for TROPION 01, obviously need OS. For field as a whole we could use structured crossover trials from ADC1–>ADC2. And we need a better understanding of resistance: resistance based on target vs payload.

George W Sledge MD avatar
George W Sledge MD@GeorgeSledge51·7 Dec 2023

TROPION Breast01 updated from October ESMO shows 2.4 mo improvement in PFS vs ineffective late line CT with improved QOL vs CT. Question: should we require, going forward, comparisons vs other ADCs rather than vs essentially inactive CT?